GLP-1 medicines have profoundly changed the treatment of obesity and overweight associated with certain clinical conditions. Molecules such as semaglutide and tirzepatide can promote significant weight loss during therapy, but one of the most important questions arises when treatment is reduced or discontinued: is it possible to maintain the weight achieved?
The answer depends greatly on the individual case. Studies show that weight regain after discontinuing GLP-1 medicines is common, and can sometimes be substantial. However, this does not mean that every patient will necessarily return to their initial weight. Weight maintenance should be considered a specific phase of the journey, to be planned through nutrition, physical activity and appropriate medical follow-up.
Yes, it is possible to maintain at least part of the weight lost after GLP-1 treatment, although it can be difficult. The available studies highlight considerable variability between individuals and show that weight regain tends to occur particularly in the months following discontinuation.
A widely cited finding comes from the extension of the STEP 1 study on semaglutide. After losing an average of 17.3% of their weight during treatment, participants regained around two-thirds of what they had lost in the year following discontinuation. At the end of the observation period, however, their average weight was still 5.6% lower than at baseline.1
These figures help explain why weight maintenance cannot be taken for granted. To explore the previous phase in more detail, we have already looked at what happens when treatment with GLP-1 medicines is discontinued. Here, however, we are interested in understanding which factors can help make the results achieved more stable.
Weight regain does not simply depend on a loss of motivation or a return to previous habits. After weight loss, the body puts physiological adaptations into place that can favour weight regain. This is compounded by the gradual disappearance of the effects exerted by the medicine during treatment.
For this reason, the rebound effect of GLP-1 therapy should be taken into account when planning the treatment pathway, rather than only when treatment is discontinued.
During therapy, GLP-1 receptor agonists act on the regulation of appetite and satiety and slow gastric emptying. When treatment is discontinued, these effects gradually diminish and hunger may become more intense again.
At the same time, the body tends to defend its weight through mechanisms that develop in response to weight loss. Reduced energy expenditure and changes in the signals that regulate hunger and satiety can therefore make it more difficult to spontaneously maintain the same calorie intake achieved during therapy.
For this reason, weight regain is considered consistent with the chronic and relapsing nature of obesity.
There is no single percentage that applies to everyone. Studies also differ in terms of the medicine used, duration of treatment, participant characteristics and length of follow-up.
A systematic review and meta-analysis published in the BMJ in 2026, which considered 37 studies and more than 9,300 participants treated with various weight-management medicines, estimated an average regain of around 0.4 kg per month after discontinuation. Based on the available data, the statistical model projected a return to pre-treatment weight after approximately 1.7 years.2
When analysing newer incretin-based medicines, such as semaglutide and tirzepatide, the estimated rate was higher, at around 0.8 kg per month, with a possible return to baseline weight after around a year and a half. However, this figure should be interpreted carefully: for these medicines, the studies included had a maximum follow-up of 12 months after discontinuation. A complete return to baseline weight is therefore a statistical projection, rather than a direct observation of what inevitably happens to every patient.
A subsequent meta-regression published in EClinicalMedicine outlined a different trajectory: in the year following discontinuation of GLP-1 medicines, an average of around 60% of the weight lost is regained, while the rate of regain tends to gradually slow down. The authors therefore hypothesise a possible plateau below the weight recorded before treatment, while also emphasising the need for longer-term data.3
Weight regain is common and often significant, while the actual amount regained remains highly variable.
While study averages describe what happens to groups of patients, they do not allow the response of an individual to be predicted precisely. Weight maintenance therefore needs to take several factors into account, from the weight loss achieved to body composition and the habits developed during treatment.
Those who achieve very substantial weight loss also have a greater amount of weight that may subsequently be regained. This does not mean that achieving a good result during treatment is negative: it simply serves as a reminder that the extent of weight loss alone does not guarantee its stability.
The maintenance phase should therefore be planned before the desired weight is reached, assessing realistic goals and any possible changes to treatment together with a healthcare professional.
During substantial weight loss, lean mass may also decrease. Preserving muscle tissue as much as possible is useful because muscle contributes to energy expenditure and supports physical function.
For this reason, it is important to maintain nutritionally adequate eating habits, with particular attention to protein intake defined according to individual needs, and to combine this with regular physical activity that includes strength and muscle-building exercises.
This issue is particularly relevant for patients undergoing GLP-1 therapy, because reduced appetite can also lead to a lower intake of protein and micronutrients. Any supplementation should therefore be assessed on the basis of nutritional status and individual needs, as part of an overall care pathway.
Weight maintenance becomes more difficult when discontinuation of the medicine also coincides with the end of follow-up. Weight, body composition, diet, physical activity and any metabolic parameters may instead require ongoing monitoring over time.
The decision to use supplements for metabolism should also form part of this assessment. Supplements may address specific nutritional needs, but they do not replace treatment, diet or physical exercise and cannot be considered a standalone solution against weight regain.
An effective strategy should build on what has been established during treatment. Waiting until weight begins to increase again before taking action can make the next phase more difficult to manage.
The pathway should be personalised together with the healthcare professionals caring for the patient, particularly when the medicine is being used for diabetes, obesity or other conditions requiring clinical monitoring.
The main goal is to find an eating pattern that can be maintained even when the medicine’s effect on appetite diminishes. Highly restrictive diets can be difficult to sustain and there is currently insufficient evidence to recommend, for example, the ketogenic diet as a universal strategy for preventing rebound after GLP-1 treatment.
It is more useful to focus on meal quality, protein and fibre intake and the nutritional density of foods, adapting quantities and distribution to individual needs.
If reduced food intake during treatment has led to deficiencies or difficulties meeting certain nutritional requirements, a healthcare professional may also consider specific supplements to support the metabolic system or other appropriate nutritional support.
Physical exercise becomes particularly important during the maintenance phase. In addition to increasing energy expenditure, resistance training helps preserve muscle mass, while aerobic activity contributes to cardiometabolic health.
A randomised study evaluating the period following treatment with liraglutide showed interesting results: in the year after the intervention ended, those who had followed a programme of supervised physical exercise during the treatment pathway maintained their weight and body composition better than those who had received the medicine alone. The finding reinforces the idea that habits developed during treatment may also have effects during the subsequent phase.
Stopping a GLP-1 medicine does not necessarily mean ending every form of treatment. Depending on the clinical situation, the doctor may assess different maintenance strategies, which may include continuing therapy, adjusting the dose or considering other treatment options.
There is therefore no single discontinuation protocol that applies to everyone. In particular, treatment should not be modified or discontinued without medical guidance, especially in patients taking these medicines for diabetes.
This remains one of the open questions. In 2025, the World Health Organization published its first global guidelines on the use of GLP-1 medicines for obesity and identified liraglutide, semaglutide and tirzepatide as possible long-term treatments for adults with obesity, as part of a pathway that includes nutrition, physical activity and professional support.
This does not mean that every patient must take the same medicine for life. Evidence on the optimal duration of treatment, management of discontinuation and very long-term weight maintenance is still limited.
The more useful question therefore becomes which strategy can manage each patient’s condition over time. For some people, this may mean continuing treatment; for others, it may be necessary to modify or discontinue it under medical supervision, while at the same time strengthening the other tools used to manage weight.
Maintaining weight after GLP-1 treatment mainly requires avoiding expectations that are too rigid. A change on the scales after discontinuation does not automatically mean losing all the benefits achieved, and the success of the pathway should not be measured solely by the ability to maintain the lowest weight reached.
A realistic goal may be to limit weight regain, preserve muscle mass and maintain habits over time that are compatible with everyday life.
It also means acting early when appetite increases or weight starts to change, rather than waiting until there has been a complete return to the previous situation before speaking to a doctor or nutritionist.
The latest evidence increasingly supports considering obesity as a chronic and relapsing condition that may require long-term care. Medication therefore represents one of the tools available within a broader treatment pathway.
For this reason, maintaining weight after GLP-1 therapy may be possible, but it requires a strategy developed over time. Nutrition, physical activity, body composition, any nutritional support and clinical monitoring should continue to be assessed even when treatment changes or is discontinued.
The real goal therefore becomes making the benefits achieved sustainable over the long term, adapting the pathway to the body’s responses and the needs of the individual.
References